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Spontaneously arising tumours, preferentially in older mice 
may represent an interesting model for immune therapy. 
 
Symposium: Focus on the pelvic region  
 
 
SP-0507  
Bladder variability for pelvic radiotherapy: its approaches 
and impact 
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It is clear that the bladder as an organ has marked shape and 
positional variability due to its function of storing urine 
before the call of nature. This has obvious repercussions for 
pelvic radiotherapy depending on the intent of treatment 
particularly if the bladder itself is the radiotherapeutic 
target. As an organ-at-risk (OAR) this variability can be 
important and this can also impact on adjacent organs such 
as the prostate, rectum and uterus if these latter organs are 
being treated with radiotherapy. These adjacent pelvic 
organs can also deform the bladder. In addition the setup 
position of the patient either supine or prone can also 
influence on the day-to-day bladder position and shape. 
Furthermore the kidneys filtered continuously thus there will 
be steady filling of the bladder with a rate dependant on the 
hydration status of the patient during radiotherapy delivery. 
Other factors may also be crucial such as bladder capacity 
and function as well as disease extent if there is bladder 
cancer. Therefore the variability of the bladder size and 
shape is an important consideration for any pelvic 
radiotherapy. Many investigators have reported on the 
marked difference in filling of the bladder with variation in 
bladder size that may range up to 20 mm on different 
scanning times during a course of fractionated radiotherapy. 
For primary bladder radiotherapy, identification of the 
disease extent remains important as both the target and 
tissue of tolerance is the bladder itself. This can also impact 
on the manner in which the bladder fills in 3D and be 
distorted by invasive bladder disease. It can be difficult to 
maintain daily consistency of the 3D shape and size thus 
there are several methods developed to deal with this 
including treatment with either an empty or comfortably full 
bladder to initiating adaptive planning and image guided 
delivery methods. Fiducials have been used to better target 
the main disease for either boosting disease or to incorporate 
focal therapy strategies. These methods can also permit 
organ avoidance if the bladder is an OAR and it is critical to 
minimise dose to it due to poor bladder function and other 
clinical factors. If the bladder is not the target then it can 
perform a useful function with intended filling prior to 
radiotherapy in order to displace other pelvic organs such as 
the bowel from irradiation such as with treatment of the 
pelvic nodes. Thus patient and disease related factors will 
need to be carefully assessed for each case. All these 
methods including their rationale and effectiveness will be 
discussed for both situations of the bladder as a target and as 
an OAR. 
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Background: Implantation of fiducial markers for IGRT 
(Image Guided Radiation Therapy) of prostate cancer patients 
increases the treatment accuracy by prostate localization 
using two orthogonal X-rays images. However the precision of 
the treatment depends on the stability of the fiducial 
marker. The aim of this study was to evaluate the migration 
of fiducial markers during the whole radiotherapy of prostate 
cancer patients.  
 
Material and methods: An analysis of the intraprostatic 
fiducials migration during the treatment planning was done 
on a group of 45 patients on the basis on fusion of kV CBCT 
(performed during the first week of the treatment) and 
planning CT. The value of migration during the course of 
radiotherapy was done on a group of 20 patients treated 
within IGRT protocol on the basis on the fusion of kV CBCTs, 
performed weekly. The migration was defined as a shift 
between central points of markers, measured in three axis.  
 
Results: The average values of the GoldAnchor™ migration 
during the treatment planning were: 1.1 mm (SD=0.9 mm) in 
the superior-inferior (SI) direction, 0.5 mm (SD=0.6 mm) in 
the left-right (LR) direction and 1.1 mm (SD=1.2 mm) in the 
anterior-posterior (AP) direction. The mean value of the 
vector of shifts was 1.9 mm (SD=1.3 mm). The average values 
of the GoldAnchor™ migration during the course of 
radiotherapy were: 0.1 mm (SD=0.2 mm) in the superior-
inferior (SI) direction, 0.1 mm (SD=0.3 mm) in the left-right 
(LR) direction and 0.2 mm (SD=0.4 mm) in the anterior-
posterior (AP) direction. The mean value of the vector of 
shifts during the treatment was 0.3 mm (SD=0.5 mm).  
 
Conclusions: The analysis of the collected data showed that 
the marker shifts during the treatment planning seems to 
have no clinical significance and probably are related to the 
inaccuracy of the fusion of kV CBCT and planning CT. Position 
of the marker is stable during the whole course of 
radiotherapy. Therefore, IGRT based on GoldAnchor™ 
markers is safe and effective method of prostate cancer 
patient positioning. 
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Purpose: To comply a decision aid tool with the criteria of 
the International Patient Decision Aid Standards (IPDAS), it is 
mandatory to follow a systematic and iterative approach to; 
(a) understand patient’s and clinicians decisional needs, (b) 
create prototypical tools, (c) evaluate these prototypes with 
patients and clinicians and (d) use these results to improve 
the tool. We developed and validated a web-based decision 
aid (DA) for shared decision making in prostate cancer 
patients using this approach.  
Methods: A prototype of the tool was designed based on the 
input of an interdisciplinary group. Its clarity and 
acceptability was tested using a mixed method (interview 
and technology acceptance questionnaire; 5-Likert scale). 
The evaluation was performed with physicians (N=19) and 
patients (N= 16). Professionals from 5 academic and private 
hospitals (urologists, radiotherapists, specialized nurses and 
family doctors) gave their perspective about the patients’ 
decisional needs and validated the information about the 
treatment options, complications and outcomes. The 
included patients were treated with either external beam 
radiotherapy, brachytherapy or prostatectomy. Patients who 
choose not to be treated (active surveillance) were also 
included. The decisional needs were evaluated during an 
interview. Afterwards the patients’ were guided through the 
DA and asked to fill in a questionnaire to check the 
comprehensibility of the tool. A second group of patients 
(N=8) was included to assess the e-learning effect of the DA 
and to check if patients were able to use the DA alone 
(without coaching).  
 
Results: The results were considered to create a new version 
of the DA. Physicians mentioned the need of information 
about basic anatomy, contraindications, hospital specific 
figures, and psychological support. Patients reported that the 
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prototype of the DA provides clear information about the 
treatment options and their side-effects. Issues about the 
usability of the DA were reported and enabled us to improve 
and simplify the DA. The next step is to perform a study to 
establish the impact of the DA on the decisional conflict and 
the shared decision making process.  
 
Conclusion: The systematic and iterative approach used to 
develop and validate the DA, allows to follow a thoroughly 
development process, and to gain knowledge about decisional 
needs.  
 
Poster Viewing: 11: Clinical: Breast, head and neck  
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Purpose or Objective: Van Werkhoven et al. developed a 
nomogram to predict the 10-years ipsilateral breast relapse 
(IBR) after breast conserving therapy (BCT) for breast cancer 
(BC) based on the European Organisation for Research and 
Treatment of Cancer (EORTC) ‘boost no boost’-trial with a 
concordance probability estimate (CPE) of 0.68 (van 
Werkhoven E, et al. 2011, Radiother Oncol). The nomogram 
includes histologic grade, ductal carcinoma in situ (DCIS), 
tumour diameter, age, tamoxifen, chemotherapy and boost. 
The aim of this study was to evaluate the performance of 
that algorithm in an independent cohort. 
 
Material and Methods: We retrospectively identified 1866 BC 
patients who underwent BCT with radiotherapy from 2000 to 
2007.  
Two definitions of IBR were considered where simultaneous 
regional or distant recurrence were either censored (conform 
EORTC analysis) or included as event.  
Patient, tumour and treatment characteristics were 
evaluated in uni- and multivariable analysis.  
Firstly we assessed discrimination, i.e. the extent to which 
patients predicted to be at higher risk exhibit higher event 
rates than those deemed at lower risk, by the CPE. The CPE 
was determined based on a Cox model with time to IBR as 
outcome and the EORTC nomogram 10-years IBR-free 
probability as the only covariate. Secondly a calibration plot 
was drawn, showing the predicted 10-years IBR-free 
probabilities against observed Kaplan–Meier estimates, to 
reflect prediction accuracy, i.e. the absence of over- or 
underestimation. 
 
Results: Median follow-up time was 10.75 years.  
Patients were on average older (58 vs 54 years), had a larger 
average tumour diameter (18 mm vs 15 mm) and were more 
likely to have received chemotherapy (29.7 % vs 15.7 %), to 
have a high grade disease (37.0 % vs 23.5 %) and to have a 
DCIS (69.8 % vs 57.8 %). Twenty-three percent of the patients 
received tamoxifen in the EORTC group, whereas 81.6 % 
received hormonal therapy in the validation group. Almost all 
patients (99.7 %) in the validation group received a boost 
versus 50.4 % in the EORTC cohort. Noteworthy on the 
variables not included in the nomogram, patients in the 
validation cohort had a higher percentage of oestrogen and 
progesterone receptor positivity (86.4 % vs 71.7 % and 75.9 % 
vs 64.3 %, respectively) and 10.2 % had HER2 overexpression. 
The 10-years IBR-rate was 1.4 %. On multivariable analysis, 
only the omission of the boost dose was a significant 
prognosticator of IBR (p < 0.01) with a trend for age (p = 
0.06).  
The nomogram demonstrated suboptimal discrimination, with 
a CPE of 0.54, and suboptimal calibration with an 
overestimation of the IBR-risk in general (Table 1 – Figure 1). 
 
 
 
 
Conclusion: The EORTC predictive model for IBR in BC 
patients lacks accuracy in this more recent study population. 
Therefore the model should be tested and verified in 
additional, large patient populations and incorporating 
molecular subtyping might be needed. 
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Purpose or Objective: To evaluate acute toxicity and early 
clinical outcomes of hypofractionated simultaneous 
integrated boost (SIB) approach with Volumetric Modulated 
Arc Therapy (VMAT) as adjuvant treatment after breast-
conserving surgery. 
 
Material and Methods: Patients presenting early-stage breast 
cancer were enrolled in a phase II trial. Eligibility criteria 
were as follow: age >18  years, invasive cancer or DCIS, Stage 
I to II (T <3 cm and N ≤ 3), breast -conserving surgery, any 
systemic therapy was allowed in neoadjuvant or adjuvant 
setting. All patients underwent VMAT-SIB technique to 
irradiate the whole breast with concomitant boost irradiation 
of the tumor bed. Doses to whole breast and surgical bed 
were 40.5 Gy and 48 Gy respectively, delivered in 15 
fractions over 3 weeks Acute skin toxicities were recorded 
according to RTOG scoring criteria, and late skin toxicities 
according to CTCAE v4.0. Cosmetic outcomes were assessed 
as excellent/good or fair/poor according to the Harvard 
scale. 
 
Results: Between August 2010 and January 2015, 840 
consecutive patients were treated. Median age was 60 year 
(range 19-89 years). The median follow up was 16 months 
(range 6-55). At the end of RT treatment skin toxicity profile 
was G1 in 49% of the patients, G2 in 13%, and one patients 
presented G3 toxicity (0.1%). At six months of follow up skin 
toxicity was G1 in 27% of patients, G2 in 1%, no G3 cases; 
